PAR-19-356: NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) - 0 views
-
MiamiOH OARS on 12 Sep 19This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; innovative preclinical studies, including the use of new clinically-relevant models and imaging technologies, which could lead to first-in-human clinical trials, and therapeutic outcome disparities, including biomarkers or genetic/epigenetic signatures, among diverse racial/ethnic populations, including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines.